COSCIENS Biopharma Inc.
CSCIF · OTCMCIK 1113423fmd_12PM3P384PFH99P7TJXTW2QFNHManufacturing · Perfumes, Cosmetics & Other Toilet PreparationsTemplate: Standard
Coverage: Jan 01, 2015 to Dec 31, 2025, 34 periods
Latest annual · FY2025
Millions- Total revenues
- 7
- Gross profit
- 3
- Operating income
- (11)
- Net income
- (10)
- Free cash flow
- (9)
Latest quarter · Q4 FY2025
Millions- Total revenues
- 2
- Gross profit
- 1
- Operating income
- (2)
- Net income
- (2)
- Free cash flow
- (2)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2022 to FY2025
- -19.9%
- Revenue, 5 yearsFY2020 to FY2025
- +15.5%
- Net income, 5 yearsFY2020 to FY2025
- n/m
COSCIENS Biopharma Inc. (CSCIF) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $7.5 million | $9.6 million | -21.8% | 20-F 2026-03-25 · proof |
| Gross profit | $2.6 million | $4.7 million | -44% | 20-F 2026-03-25 · proof |
| Operating income | -$10.7 million | -$18.3 million | 20-F 2026-03-25 · proof | |
| Net income | -$10.4 million | -$15.3 million | 20-F 2026-03-25 · proof | |
| Cash from operating activities | -$8.5 million | -$14.6 million | 20-F 2026-03-25 · proof | |
| Free cash flow | -$9.2 million | -$15.7 million | 20-F 2026-03-25 · proof | |
| Total assets | $21.4 million | $35.1 million | -38.9% | 20-F 2026-03-25 · proof |
| Total liabilities | $17.6 million | $21.9 million | -19.7% | 20-F 2026-03-25 · proof |
| Cash and cash equivalents | $7.3 million | $16.4 million | -55.4% | 20-F 2026-03-25 · proof |
- What was COSCIENS Biopharma Inc. (CSCIF)'s revenue in fiscal 2025?
- COSCIENS Biopharma Inc. (CSCIF) reported revenue of $7.5 million for fiscal 2025 (the year ended Dec 31, 2025), against $9.6 million the year before (-21.8%). Source: the 20-F filed with the SEC on Mar 25, 2026. SEC
- What was COSCIENS Biopharma Inc. (CSCIF)'s gross profit in fiscal 2025?
- COSCIENS Biopharma Inc. (CSCIF) reported gross profit of $2.6 million for fiscal 2025 (the year ended Dec 31, 2025), against $4.7 million the year before (-44%). Source: the 20-F filed with the SEC on Mar 25, 2026. SEC
- What was COSCIENS Biopharma Inc. (CSCIF)'s operating income in fiscal 2025?
- COSCIENS Biopharma Inc. (CSCIF) reported operating income of -$10.7 million for fiscal 2025 (the year ended Dec 31, 2025), against -$18.3 million the year before. Source: the 20-F filed with the SEC on Mar 25, 2026. SEC
- What was COSCIENS Biopharma Inc. (CSCIF)'s net income in fiscal 2025?
- COSCIENS Biopharma Inc. (CSCIF) reported net income of -$10.4 million for fiscal 2025 (the year ended Dec 31, 2025), against -$15.3 million the year before. Source: the 20-F filed with the SEC on Mar 25, 2026. SEC
- What was COSCIENS Biopharma Inc. (CSCIF)'s cash from operating activities in fiscal 2025?
- COSCIENS Biopharma Inc. (CSCIF) reported cash from operating activities of -$8.5 million for fiscal 2025 (the year ended Dec 31, 2025), against -$14.6 million the year before. Source: the 20-F filed with the SEC on Mar 25, 2026. SEC
- What was COSCIENS Biopharma Inc. (CSCIF)'s free cash flow in fiscal 2025?
- COSCIENS Biopharma Inc. (CSCIF) reported free cash flow of -$9.2 million for fiscal 2025 (the year ended Dec 31, 2025), against -$15.7 million the year before. Source: the 20-F filed with the SEC on Mar 25, 2026. SEC
- What are COSCIENS Biopharma Inc. (CSCIF)'s total assets?
- As of Dec 31, 2025, COSCIENS Biopharma Inc. (CSCIF) reported total assets of $21.4 million, against $35.1 million a year earlier (-38.9%). Source: the 20-F filed with the SEC on Mar 25, 2026. SEC
- What are COSCIENS Biopharma Inc. (CSCIF)'s total liabilities?
- As of Dec 31, 2025, COSCIENS Biopharma Inc. (CSCIF) reported total liabilities of $17.6 million, against $21.9 million a year earlier (-19.7%). Source: the 20-F filed with the SEC on Mar 25, 2026. SEC
- What are COSCIENS Biopharma Inc. (CSCIF)'s cash and cash equivalents?
- As of Dec 31, 2025, COSCIENS Biopharma Inc. (CSCIF) reported cash and cash equivalents of $7.3 million, against $16.4 million a year earlier (-55.4%). Source: the 20-F filed with the SEC on Mar 25, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:CSCIF&period_type=annual&limit=5"Information only, not investment advice.